Lung cancer combo therapy trial stopped early
NCT ID NCT03366766
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested giving the immunotherapy drug nivolumab along with chemotherapy before surgery for people with early-stage non-small cell lung cancer (stages I to IIIA). The goal was to see if this combination could shrink tumors enough to leave less than 10% cancer cells in the removed tissue. The trial was stopped early after enrolling only 14 participants, so results are limited.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SQUAMOUS NON-SMALL CELL LUNG CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Abington Hospital - Jefferson Health
Abington, Pennsylvania, 19001, United States
-
Sidney Kimmel Cancer Center at Thomas Jefferson University
Philadelphia, Pennsylvania, 19107, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an immunotherapy cocktail shrink inoperable lung tumors?
- New hope: targeted pill before surgery for lung cancer
- New combo therapy aims to boost lung cancer fight
- Lung cancer clues: old data may reveal best Pre-Surgery treatments
- New combo therapy for lung cancer shows promise in early trial
- New combo therapy for lung cancer shows promise in early trial